Sangivamycin - OyaGen/National Institute of Allergy and Infectious Diseases
Alternative Names: OYA-1; Sangivamycin - OyaGen; TNX-3500Latest Information Update: 28 Apr 2024
At a glance
- Originator OyaGen
- Developer National Institute of Allergy and Infectious Diseases; OyaGen
- Class Antivirals; Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ebola virus infections
- No development reported COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (IV, Injection)
- 18 Sep 2023 OyaGen plans a phase I trial for COVID-2019 infection in USA
- 29 Aug 2023 OyaGen has patent protection for sangivamycin in the treatment of COVID infections in USA